<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Endocrinol Metab (Seoul)</journal-id><journal-id journal-id-type="iso-abbrev">Endocrinol Metab (Seoul)</journal-id><journal-id journal-id-type="publisher-id">ENM</journal-id><journal-title-group><journal-title>Endocrinology and Metabolism</journal-title></journal-title-group><issn pub-type="ppub">2093-596X</issn><issn pub-type="epub">2093-5978</issn><publisher><publisher-name>Korean Endocrine Society</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">28956360</article-id><article-id pub-id-type="pmc">5620027</article-id><article-id pub-id-type="doi">10.3803/EnM.2017.32.3.316</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title>Effects of Incretin-Based Therapies on Diabetic Microvascular Complications</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Kang</surname><given-names>Yu Mi</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-4043-2396</contrib-id><name><surname>Jung</surname><given-names>Chang Hee</given-names></name><xref ref-type="aff" rid="A2">2</xref></contrib></contrib-group><aff id="A1"><label>1</label>International Healthcare Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.</aff><aff id="A2"><label>2</label>Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.</aff><author-notes><corresp>Corresponding author: Chang Hee Jung. Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul 05505, Korea. Tel: +82-2-3010-1418, Fax: +82-2-3010-6962, <email>chjung0204@gmail.com</email></corresp></author-notes><pub-date pub-type="ppub"><month>9</month><year>2017</year></pub-date><pub-date pub-type="epub"><day>18</day><month>9</month><year>2017</year></pub-date><volume>32</volume><issue>3</issue><fpage>316</fpage><lpage>325</lpage><history><date date-type="received"><day>27</day><month>7</month><year>2017</year></date><date date-type="rev-recd"><day>08</day><month>8</month><year>2017</year></date><date date-type="accepted"><day>16</day><month>8</month><year>2017</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2017 Korean Endocrine Society</copyright-statement><copyright-year>2017</copyright-year><copyright-holder>Korean Endocrine Society</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0/</ext-link>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><p>The morbidity and mortality associated with diabetic complications impose a huge socioeconomic burden worldwide. Therefore, the ultimate goal of managing diabetes mellitus (DM) is to lower the risk of macrovascular complications and highly morbid microvascular complications such as diabetic nephropathy (DN) and diabetic retinopathy (DR). Potential benefits of incretin-based therapies such as glucagon-like peptide 1 receptor agonists (GLP-1 RAs) and dipeptidyl peptidase-4 (DPP-4) inhibitors on the diabetic macrovascular complications have been recently suggested, owing to their pleiotropic effects on multiple organ systems. However, studies primarily investigating the role of these therapies in diabetic microvascular complications are rare. Nevertheless, preclinical and limited clinical data suggest the potential protective effect of incretin-based agents against DN and DR via their anti-inflammatory, antioxidative, and antiapoptotic properties. Evidence also suggests that these incretin-dependent and independent beneficial effects are not necessarily associated with the glucose-lowering properties of GLP-1 RAs and DPP-4 inhibitors. Hence, in this review, we revisit the preclinical and clinical evidence of incretin-based therapy for DR and DN, the two most common, morbid complications in individuals with DM. In addition, the review discusses a few recent studies raising concerns of aggravating DR with the use of incretin-based therapies.</p></abstract><kwd-group><kwd>Glucagon-like peptide 1</kwd><kwd>Dipeptidyl-peptidase IV inhibitors</kwd><kwd>Diabetic microvascular complications</kwd><kwd>Effect</kwd><kwd>Retinopathy</kwd><kwd>Nephropathy</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution>National Research Foundation of Korea</institution><institution-id institution-id-type="CrossRef">http://dx.doi.org/10.13039/501100003725</institution-id></institution-wrap></funding-source><award-id>2015R1D1A1A01057720</award-id></award-group></funding-group></article-meta></front><body><sec sec-type="intro"><title>INTRODUCTION</title><p>The ultimate goal of maintaining euglycemia in individuals with diabetes mellitus (DM) is to lower the risk of morbidity and mortality associated with diabetic complications. Accordingly, the UK Prospective Diabetes Study (UKPDS) reported that compared with the conventional group, the intensive group showed a significant risk reduction by 12% in the any diabetes-related aggregate endpoint, which was mainly due to a 25% risk reduction in microvascular endpoints [<xref rid="B1" ref-type="bibr">1</xref>]. Moreover, this intensive glycemic control led to the lower rates of cardiovascular events and diabetes-related mortality 10 years later [<xref rid="B2" ref-type="bibr">2</xref>]. However, in the Korean diabetic population, the prevalence of diabetic complications remains high; the prevalence of diabetic nephropathy (DN) was 30.3% in 2016, and that of diabetic retinopathy (DR) was 15.9% in 2015 [<xref rid="B3" ref-type="bibr">3</xref>]. Unfortunately, these numbers are not significantly decreasing despite a huge improvement in antidiabetic therapies over the last few decades. Thus, an antidiabetic medication that exerts additional protective effects against diabetic complications beyond glycemic control [<xref rid="B4" ref-type="bibr">4</xref>] would certainly be ideal to further reduce diabetes-related morbidity and mortality.</p><p>Incretins are a family of gut hormones that include glucose-dependent insulinotropic polypeptide and glucagon-like peptide 1 (GLP-1) [<xref rid="B5" ref-type="bibr">5</xref>]. Recognition of the glucoregulatory role exerted by these intestinal hormones eventually led to the recent development of novel, targeted therapies for the treatment of type 2 diabetes mellitus (T2DM) [<xref rid="B4" ref-type="bibr">4</xref>]. Incretin-based therapies, such as GLP-1 receptor agonists (GLP-1 RAs) and dipeptidyl peptidase-4 (DPP-4) inhibitors, which inhibit the degradation of GLP-1 by DPP-4, have been introduced into the market in the past decade to overcome the short half-life of the endogenous incretin effect [<xref rid="B6" ref-type="bibr">6</xref>]. A body of evidence suggests that the pleiotropic effects that these incretin-based therapies possess result in a better glycemic profile, weight loss, and favorable macrovascular and microvascular outcomes [<xref rid="B7" ref-type="bibr">7</xref>]. Moreover, the low risk of hypoglycemia with incretin-based drugs can reduce the concern of hypoglycemia-induced aggravation of vascular outcomes [<xref rid="B8" ref-type="bibr">8</xref>].</p><p>Recently, there have been multiple clinical trials to determine the efficacy and cardiovascular safety of GLP-1 RAs and DPP-4 inhibitors [<xref rid="B9" ref-type="bibr">9</xref><xref rid="B10" ref-type="bibr">10</xref><xref rid="B11" ref-type="bibr">11</xref><xref rid="B12" ref-type="bibr">12</xref><xref rid="B13" ref-type="bibr">13</xref><xref rid="B14" ref-type="bibr">14</xref>]. In these trials, the impact of these agents on the microvascular complications is not well elaborated and the interpretation can be limited because the microvascular outcomes were reported as the secondary endpoint. Considering the morbidity and economic burden due to microvascular complications, more evidence is needed to evaluate the efficacy and safety of incretin-based drugs using microvascular complications as the primary endpoint. Hence, by reviewing the available, up-to-date evidence in the literature, we evaluate the effects of incretin-based therapies on DN and DR and the mechanisms through which these therapies exerted protective effects against these diabetic microvascular complications. In addition, we here address the recent issue of potential adverse effect of incretin-based therapies in DR [<xref rid="B10" ref-type="bibr">10</xref><xref rid="B15" ref-type="bibr">15</xref>].</p></sec><sec><title>POTENTIAL MECHANISM OF INCRETIN-BASED THERAPIES IN PROTECTING AGAINST MICROVASCULAR COMPLICATIONS</title><p><xref ref-type="fig" rid="F1">Fig. 1</xref> illustrates various pathways through which incretin-based therapies can potentially exert beneficial effects on diabetic microvascular complications. Incretins induce insulin secretion and suppress glucagon secretion, which improve hyperglycemia and insulin resistance [<xref rid="B16" ref-type="bibr">16</xref>]. As a result, reduced oxidative stress and advanced glycation end products (AGEs) lead to vasculoprotective effects [<xref rid="B17" ref-type="bibr">17</xref><xref rid="B18" ref-type="bibr">18</xref>]. We have previously reviewed the pleiotropic and protective effects of native GLP-1 and GLP-1 RAs on the vascular endothelium and inflammatory cells in addition to their effects on glycemic control [<xref rid="B6" ref-type="bibr">6</xref>]. Both the direct effect of GLP-1 on the microvasculature and the improvements in glycemic control and insulin resistance via the &#x0201c;incretin-dependent pathway&#x0201d; can contribute to the beneficial effects on microvascular complications.</p><p>In addition, a body of evidence suggests that incretin-based therapies exert anti-inflammatory, antioxidant, and antiapoptotic effects in the vasculature via incretin-independent pathways [<xref rid="B4" ref-type="bibr">4</xref>]. This phenomenon has been well demonstrated in studies involving DPP-4 inhibitors, since DPP-4 has actions on other substrates, in addition to its actions on incretin hormones. For example, DPP-4 exhibits protease activities on substrates such as stromal cell-derived factor 1&#x003b1; (SDF-1&#x003b1;), brain natriuretic peptide, and neuropeptide Y-1 (NPY-1); these substrates have been suggested to have regulatory effects on vascular function, such as vascular tone regulation, inflammation, cell migration, and cell differentiation [<xref rid="B19" ref-type="bibr">19</xref>]. Taken together, these findings suggest that these incretin-dependent and independent mechanisms of GLP-1 RAs and DPP-4 inhibitors can exert potentially beneficial effects on diabetic microangiopathies (<xref ref-type="fig" rid="F1">Fig. 1</xref>).</p></sec><sec><title>EVIDENCE OF INCRETIN-BASED THERAPIES IN PROTECTING AGAINST MICROVASCULAR COMPLICATIONS</title><sec><title>GLP-1 and DN</title><p>Obesity and T2DM are associated with progressive loss of renal function that could eventually result in chronic kidney disease (CKD) and end-stage renal disease [<xref rid="B20" ref-type="bibr">20</xref><xref rid="B21" ref-type="bibr">21</xref>]. Expression of GLP-1 receptors in both animal and human kidneys has been identified, especially in the glomeruli and proximal tubules [<xref rid="B22" ref-type="bibr">22</xref><xref rid="B23" ref-type="bibr">23</xref><xref rid="B24" ref-type="bibr">24</xref>]. Moreover, the increased renal DPP-4 activity in the overnutrition/obese state [<xref rid="B25" ref-type="bibr">25</xref>] and the downregulated GLP-1 receptor expression in the glomeruli in a diabetic rat model [<xref rid="B26" ref-type="bibr">26</xref>] indicate the potential benefits of incretin-based therapies against DN.</p><p>In fact, accumulated evidence from preclinical studies suggests that GLP-1 RAs exert renoprotective effects via numerous mechanisms. Mima et al. [<xref rid="B27" ref-type="bibr">27</xref>] demonstrated that exendin-4, a GLP-1 RA, mediates its renoprotective action in the glomerular endothelial cells by inhibiting angiopoietin-2 signaling and suppressing downstream inflammatory reactions, as supported by decreased mRNA levels of inflammatory markers such as plasminogen activator inhibitor 1 (PAI-1) in the renal cortex of diabetic rodents. Similarly, Ishibashi et al. [<xref rid="B28" ref-type="bibr">28</xref>] observed that GLP-1 inhibited receptor for AGE (RAGE) gene expression in mesangial cells, further reducing reactive oxygen species generation, and the gene and protein expression of monocyte chemoattractant protein-1 (MCP-1) in AGE-exposed mesangial cells. In addition, in a study using a streptozotocin (STZ)-induced rat model of type 1 diabetes mellitus (T1DM), a 4-week administration of another GLP-1 RA, liraglutide, reversed the abnormal elevation of the oxidative stress markers, NAD(P)H (nicotinamide adenine dinucleotide phosphate) oxidase, transforming growth factor &#x003b2; (TGF-&#x003b2;), fibronectin, and urinary albumin excretion, all of which were induced by STZ treatment [<xref rid="B29" ref-type="bibr">29</xref>]. Interestingly, these phenomena were observed with unchanged plasma glucose levels and body weights [<xref rid="B29" ref-type="bibr">29</xref>]. Taken together, these studies suggest that GLP-1 directly exerts renoprotective effects in both glomerular endothelial cells and mesangial cells in addition to glycemic control, by minimizing oxidative stress and inflammation.</p><p>Clinical evidence of renoprotective effects of GLP-1 RAs, albeit limited, exists. In a study of 31 T2DM patients, subjects were randomized to a GLP-1 RA arm (exenatide) or a sulfonylurea arm (glimepiride) [<xref rid="B30" ref-type="bibr">30</xref>]. After 16 weeks of treatment, 24-hour urinary albumin, urinary TGF-&#x003b2;1, and type IV collagen were significantly lower in the exenatide group than in the glimepiride group, with no significant difference in the glycemic control between the groups [<xref rid="B30" ref-type="bibr">30</xref>]. These findings suggest a direct benefit of exenatide in individuals with DN via anti-inflammatory and possibly antifibrotic mechanisms, independent of its glucose-lowering effect. In addition, GLP-1 injection to obese individuals with insulin resistance, who were overtly healthy, induced natriuresis without altering potassium excretion [<xref rid="B31" ref-type="bibr">31</xref>]. von Scholten et al. [<xref rid="B32" ref-type="bibr">32</xref>] observed antihypertensive effects as well as reversible reductions in albuminuria with a short regimen of liraglutide treatment (i.e., 7 weeks) in 31 participants with T2DM. In the latter study, similar results were reported when the investigators performed a 1-year extension study [<xref rid="B33" ref-type="bibr">33</xref>], indicating persistent hemodynamic improvement induced by GLP-1 RAs by diminishing volume expansion and glomerular hyperfiltration.</p><p>In the Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) trial, which observed favorable cardiovascular outcomes with the use of liraglutide, the risk of nephropathy was investigated as the secondary endpoint [<xref rid="B11" ref-type="bibr">11</xref>]. In this study, a long-term (i.e., 42 to 60 months) treatment with liraglutide also resulted in a reduced risk of DN (hazard ratio [HR], 0.78; 95% confidence interval [CI], 0.67 to 0.92; <italic>P</italic>=0.003), defined as the development of new onset macroalbuminuria, a doubling of the serum creatinine level and an estimated glomerular filtration rate (eGFR) of &#x02264;45 mL/min/1.73 m<sup>2</sup>, the need for continuous renal-replacement therapy, or death from renal disease [<xref rid="B11" ref-type="bibr">11</xref>]. In the Trial to Evaluate Cardiovascular and Other Long-term Outcomes with Semaglutide in Subjects with Type 2 Diabetes (SUSTAIN-6), the risk of new or worsening nephropathy was also observed as the secondary outcome, which included persistent macroalbuminuria, persistent doubling of the serum creatinine level and an eGFR of &#x02264;45 mL/min/1.73 m<sup>2</sup>, or the need for continuous renal-replacement therapy [<xref rid="B10" ref-type="bibr">10</xref>]. In this study, the HR of new or worsening DN was 0.64 (95% CI, 0.46 to 0.88; <italic>P</italic>=0.005), further emphasizing the renoprotective roles of GLP-1 RAs in DN. Results from upcoming large-sized studies, such as the Exenatide Study of Cardiovascular Event Lowering (EXSCEL) trial of exenatide or the Researching CV Events with a Weekly Incretin in Diabetes (REWIND) trial of dulaglutide, could clarify whether these renoprotective results are a class effect.</p></sec><sec><title>DPP-4 inhibitors and DN</title><p>In a rat model of T1DM, administration of DPP-4 inhibitors for 8 weeks resulted in an increased serum concentration of active GLP-1, a decreased urinary albumin excretion, and an ameliorated DN histology [<xref rid="B34" ref-type="bibr">34</xref>]. DPP-4 inhibitors prevented macrophage infiltration, downregulated inflammatory molecules, and suppressed nuclear factor-&#x003ba;B (NF-&#x003ba;B) activity in the kidney [<xref rid="B34" ref-type="bibr">34</xref>]. All of these effects were observed without significant changes in glycemic profiles, suggesting that DPP-4 inhibitors exert anti-inflammatory and antifibrotic renoprotective effects by increasing the serum concentration of active GLP-1. Such renoprotective effects of commercially available DPP-4 inhibitors, including sitagliptin, linagliptin, and vildagliptin, have also been demonstrated in numerous animal studies [<xref rid="B35" ref-type="bibr">35</xref><xref rid="B36" ref-type="bibr">36</xref><xref rid="B37" ref-type="bibr">37</xref><xref rid="B38" ref-type="bibr">38</xref>].</p><p>However, the increased activity of NPY owing to the inhibition of DPP-4 (i.e., an incretin-independent effect) has been suggested in an animal model, which enhances the renovascular effects of angiotensin II [<xref rid="B39" ref-type="bibr">39</xref><xref rid="B40" ref-type="bibr">40</xref>]. Therefore, it is possible that the enhanced NPY activity owing to the inhibition of the protease activity of DPP-4 ameliorate the effect of antihypertensives such as angiotensin-converting enzyme inhibitors (ACEi). This finding raises a concern, because ACEi are commonly prescribed as first-line antihypertensive agents to control blood pressure in patients with DM, who might also be using DPP-4 inhibitors. However, in the aforementioned studies, there was no evidence that the enhanced NPY activity led to aggravated DN. Moreover, inhibition of diverse substrate-specific actions following administration of DPP-4 inhibitors can lead to various downstream results (<xref ref-type="fig" rid="F1">Fig. 1</xref>). Therefore, more study results will be needed to assess the overall risk-benefit of administering DPP-4 inhibitors in humans.</p><p>A few clinical studies also demonstrated the effects of DPP-4 inhibitors on the renal function of patients with DM. Sitagliptin [<xref rid="B41" ref-type="bibr">41</xref>], alogliptin [<xref rid="B42" ref-type="bibr">42</xref>], vildagliptin [<xref rid="B43" ref-type="bibr">43</xref>], and linagliptin [<xref rid="B44" ref-type="bibr">44</xref>] decreased albuminuria in patients with T2DM. Interestingly, the effect of sitagliptin in reducing albuminuria was observed 6 months after the initiation of therapy, for which the authors suggested that the lowering effect of eGFR by sitagliptin was dependent on improved dysglycemia and blood pressure [<xref rid="B41" ref-type="bibr">41</xref><xref rid="B45" ref-type="bibr">45</xref>]. However, because the serum levels of high-sensitivity C-reactive protein and soluble vascular cell adhesion protein 1 were also reduced after 6 months of sitagliptin treatment in this study [<xref rid="B41" ref-type="bibr">41</xref>], it is plausible that some anti-inflammatory properties of the DPP-4 inhibitor had contributed to this effect. Fujita et al. [<xref rid="B42" ref-type="bibr">42</xref>] conducted a crossover study of T2DM patients who were treated with sitagliptin for 4 weeks, switched to alogliptin for 4 weeks, and then returned to sitagliptin treatment for an additional 4 weeks. Interestingly, urinary albumin and oxidative stress marker (i.e., 8-hydroxy 2'-deoxyguanosine [8-OHdG]) levels significantly decreased and the plasma SDF-1&#x003b1; level significantly increased during the alogliptin treatment compared to the levels during the sitagliptin treatment [<xref rid="B42" ref-type="bibr">42</xref>], suggesting that alogliptin exerts a stronger renoprotective effect via an incretin-independent, antioxidant mechanism. In addition, administration of linagliptin for 24 weeks reduced the albumin-creatinine ratio by 32% compared to 6% in the placebo group, without significant changes in hemoglobin A1c (HbA1c) and blood pressure [<xref rid="B44" ref-type="bibr">44</xref>]. Hence, it is still unclear whether DPP-4 inhibitors exert their renoprotection via direct effects, better glycemic control, or both.</p><p>Some large clinical trials included renal outcome as their secondary endpoint. For example, the Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus-Thrombolysis in Myocardial Infarction (SAVOR-TIMI 53) trial reported a significant reduction in albuminuria, when examining the treatment difference in the number and proportions of patients with worsening, no change, or improvement in albumin/creatinine ratio, pre-specified as a shift from baseline category at 1, 2 year, and end of treatment [<xref rid="B13" ref-type="bibr">13</xref>].</p><p>The Efficacy, Safety and Modification of Albuminuria in Type 2 Diabetes Subjects with Renal Disease with LINAgliptin (MARLINA-T2D) study [<xref rid="B46" ref-type="bibr">46</xref>] was a 24-week, prospective, randomized, placebo-controlled, phase 3b clinical trial. It evaluated the renal outcomes (i.e., albuminuria and progression of CKD) as the primary endpoint in T2DM patients who had pre-study DN and were receiving current standard of care, including ACEi or angiotensin receptor blockers. In this study, linagliptin reduced the urinary albumin/creatinine ratio, but not to a statistically significant extent when adjusted for the results of the placebo group (i.e., mean change, &#x02212;6.0%; 95% CI, &#x02212;15.0 to 3.0; <italic>P</italic>=0.1954) [<xref rid="B46" ref-type="bibr">46</xref>]. There was no new case of CKD, but linagliptin did not significantly affect eGFR of the subjects [<xref rid="B46" ref-type="bibr">46</xref>]. The investigators of the MARLINA-T2D study proposed that their study subjects showed lower reductions in albuminuria compared to those in the SAVOR-TIMI 53 study, because the MARLINA-T2D study population contained insufficient numbers of advanced CKD patients to fully unveil the anti-albuminuric effect of linagliptin [<xref rid="B46" ref-type="bibr">46</xref>]. Nevertheless, consistent with the results of the aforementioned preclinical studies, these clinical trials also support the potentially renoprotective effect of DPP-4 inhibitors, although the exact mechanism is yet to be discovered.</p></sec><sec><title>GLP-1 and DR</title><p>DR is a major diabetic microvascular complication that can lead to decreased visual acuity and blindness [<xref rid="B47" ref-type="bibr">47</xref>]. Increased vascular permeability, edema, recruitment of inflammatory cells, elevated cytokine levels, tissue damage, and neovascularization have been observed in DR, implicating oxidative stress and inflammation as the key mechanisms [<xref rid="B48" ref-type="bibr">48</xref>].</p><p>Early signs in the pathogenesis of DR include retinal neurodegeneration [<xref rid="B49" ref-type="bibr">49</xref>] and vascular leakage due to damage to the blood-retinal barrier (BRB), which is formed by tight junction structures that link retinal vascular endothelial (VE) cells [<xref rid="B50" ref-type="bibr">50</xref>]. Albeit limited, evidence exists that GLP-1 RAs might reverse these early pathologic findings in DR [<xref rid="B49" ref-type="bibr">49</xref><xref rid="B51" ref-type="bibr">51</xref>]. Hernandez et al. [<xref rid="B49" ref-type="bibr">49</xref>] first identified the expression of GLP-1 and GLP-1 receptors in the human retina, and observed that systemic treatment with liraglutide prevented retinal neurodegeneration in <italic>db/db</italic> mice via activation of the AKT pathway, which is essential for the survival of retinal neurons. In this study, liraglutide, native GLP-1, lixisenatide, or exenatide was also administered topically to delineate whether the protective effect of GLP-1 against DR was attributable to its glucose-lowering effect. As a result, topical administration of each of the aforementioned agents replicated the same protective effect, suggesting that GLP-1 and GLP-1 RAs exert neuroprotective effects in the retina of a diabetic animal model, regardless of the blood glucose levels and the type of GLP-1 RA [<xref rid="B49" ref-type="bibr">49</xref>].</p><p>Intraocular pressure-induced retinal ischemia-reperfusion injury provides a useful model of DR that is characteristic of vascular endothelial growth factor (VEGF)-driven vascular permeability followed by inflammatory response that maintains BRB loss [<xref rid="B52" ref-type="bibr">52</xref>]. Goncalves et al. [<xref rid="B51" ref-type="bibr">51</xref>] used this technique to induce BRB breakdown and inflammation, and observed that treatment with exendin-4 significantly reduced the BRB permeability, which was associated with a decreased mRNA expression of proinflammatory cytokines, including interleukin-1&#x003b2; (IL-1&#x003b2;), IL-6, tumor necrosis factor, and C-C motif chemokine ligand 2. In addition, because the intraocular pressure-induced retinal ischemia-reperfusion injury model does not alter systemic metabolic pathways, the authors concluded that the protective effect of GLP-1 against DR was attributable to its direct effect on diabetic retinas beyond glycemic control [<xref rid="B51" ref-type="bibr">51</xref>]. They also observed reduced inflammatory response to lipopolysaccharide and inhibited NF-&#x003ba;B activation with exendin-4 treatment in cultured cells [<xref rid="B51" ref-type="bibr">51</xref>]. Similarly, Fan et al. [<xref rid="B53" ref-type="bibr">53</xref>] observed that intravitreal injections of exendin-4 in a rat model protected BRB from vascular leakage via the downregulation of tight junction proteins (i.e., claudin-5 and occludin). Taken together, these findings suggest that GLP-1 and GLP-1 RAs possess a protective effect against DR by reversing and preventing early changes, such as neurodegeneration and BRB permeability, via their antiapoptotic and anti-inflammatory mechanisms.</p><p>Unlike the protective effect observed in the aforementioned preclinical studies, studies on the role of GLP-1 and GLP-1 RAs in humans are limited and inconclusive. For example, in 2011, Varadhan et al. [<xref rid="B54" ref-type="bibr">54</xref>] observed transient worsening of DR in 30% of diabetic subjects treated with GLP-1 RA, which was associated with a rapid reduction in HbA1c levels. This finding was rather surprising because, theoretically, incretin-based drugs, such as GLP-1 RA, were considered to have very low capacities to provoke hypoglycemia, which is a risk factor for aggravating DR as garnered from previous studies [<xref rid="B55" ref-type="bibr">55</xref>]. These results clearly emphasize the need for further clinical studies to evaluate the potential effectiveness of GLP-1 RA for DR.</p><p>Several recent clinical trial results evaluating cardiovascular safety have reported DR as the secondary outcome. In the LEADER study, the incidence rate of DR, defined as the need for retinal photocoagulation or treatment with intravitreal agents, vitreous hemorrhage, or the onset of diabetes-related blindness, was slightly higher in the liraglutide group (i.e., 0.6 events/100 patient-years) than in the placebo group (i.e., 0.5/100 patient-years), and the HR for DR was 1.15 (95% CI, 0.87 to 1.52), although it did not reach statistical significance (<italic>P</italic>=0.33) [<xref rid="B11" ref-type="bibr">11</xref>]. Because the differences in glycemic control between the two treatment groups over a long period of follow-up (a median of 3.8 years) were subtle (i.e., a mean difference, &#x02212;0.40% points; 95% CI, &#x02212;0.45 to &#x02212;0.34), the possibility of GLP-1 RAs worsening DR independently of glycemic control cannot be ruled out, despite the lack of statistical significance.</p><p>In September 2016, SUSTAIN-6 study investigators reported the superiority of semaglutide for cardiovascular complications [<xref rid="B10" ref-type="bibr">10</xref>]. However, in this study, rates of DR (vitreous hemorrhage, blindness, or conditions requiring treatment with an intravitreal agent or photocoagulation) were significantly higher in the semaglutide group (HR, 1.76; 95% CI, 1.11 to 2.78; <italic>P</italic>=0.02) than in the placebo group [10]. As a response to rising concerns of the potential association of GLP-1 RAs and DR, further insights were provided by the SUSTAIN-6 investigators at the 77th scientific session of the American Diabetes Association [<xref rid="B56" ref-type="bibr">56</xref>]. There were 79 DR events that were adjudicated by an external event adjudication committee (EAC), 50 (3.0%) of which occurred in the semaglutide arm and 29 (1.8%) in the placebo arm [<xref rid="B56" ref-type="bibr">56</xref>]. Further analysis revealed that the subjects with EAC-confirmed events had a longer duration of diabetes, higher HbA1c levels, and higher percentages of insulin treatment, which suggests that those with the DR events during the study period had more progressed DM at baseline [<xref rid="B56" ref-type="bibr">56</xref>]. In addition, those with the retinopathy events had much higher incidences of DR medical history, proliferative diabetic retinopathy (PDR), and treatment with laser therapy or intravitreal agents due to the PDR; they also showed a much steeper, dose-dependent decline in HbA1c within the first 16 weeks, compared with that of the overall study population [<xref rid="B56" ref-type="bibr">56</xref>]. Subgroup analysis revealed that, among patients without a history of DR, the risk of retinopathy complications was low and comparable for both the semaglutide and placebo arms [<xref rid="B56" ref-type="bibr">56</xref>].</p><p>There are several noteworthy points that should be addressed before drawing any premature conclusions on the association between GLP-1 RAs and the progression of DR. First, the SUSTAIN-6 study had a shorter duration of follow-up (i.e., 2 years) compared to that of the LEADER study (i.e., 3.8 years). Hence, this shorter follow-up period could not have provided enough time to obtain a sufficient outcome using the standard methods for measuring DR progression [<xref rid="B7" ref-type="bibr">7</xref><xref rid="B10" ref-type="bibr">10</xref><xref rid="B11" ref-type="bibr">11</xref>]. There also was a lack of detailed evaluation for the DR at the initiation of the trials. For example, a criterion for dilation, as well as a grading system of the retinopathy did not exist, and any study investigator, optometrist, or ophthalmologist could perform the examinations [<xref rid="B7" ref-type="bibr">7</xref><xref rid="B56" ref-type="bibr">56</xref>]. Hence, data from future clinical trials of GLP-1 RAs with DR as an outcome with more precise randomization and detailed evaluation of DR at baseline and at follow-up should be accumulated to judge whether this is a class effect. Moreover, the beneficial effect of GLP-1 on outcomes other than DR should always be considered when evaluating the risk-benefit profile of GLP-1 RAs, because favorable cardiovascular and renal outcomes can lead to overall reductions in morbidity and mortality among patients with DM.</p></sec><sec><title>DPP-4 inhibitors and DR</title><p>Goncalves et al. [<xref rid="B57" ref-type="bibr">57</xref>] evaluated the effect of sitagliptin administration on the changes in the tight junction in a T2DM animal model (i.e., Zucker diabetic fatty rats); thereby, determining the permeability of BRB, a hallmark of DR development. In this study, 6-week treatment with sitagliptin (10 mg/kg/day) resulted in a better glycemic outcome, and prevented the changes in the glucose-mediated damage of the BRB [<xref rid="B57" ref-type="bibr">57</xref>]. Sitagliptin administration did not alter the total level of tight junction proteins (i.e., occludin and claudin-5), but it attenuated the intracellular accumulation of these proteins that was induced by DM [<xref rid="B57" ref-type="bibr">57</xref>]. This redistribution of tight junction proteins implicates junctional complex stabilization, which leads to maintenance of BRB integrity, leading to the protective effect of sitagliptin against DR [<xref rid="B57" ref-type="bibr">57</xref>].</p><p>In addition, Goncalves et al. [<xref rid="B57" ref-type="bibr">57</xref>] observed that sitagliptin administration ameliorated the decrease in the number of endothelial progenitor cells (EPCs) in a T2DM animal model. EPCs are stem cells that are indicative of the endogenous endothelial regenerative capacity and neovascularization, through which vascular protection is provided (<xref ref-type="fig" rid="F1">Fig. 1</xref>) [<xref rid="B58" ref-type="bibr">58</xref>], and T2DM is associated with reduced circulating EPCs [<xref rid="B59" ref-type="bibr">59</xref>]. Collectively, findings from this preclinical study suggest that sitagliptin attenuates diabetes-related damages to the BRB by stabilizing the tight junction proteins and by enhancing vascular homeostasis through the mobilization of EPCs. This team also observed similar anti-inflammatory and antiapoptotic effects of sitagliptin in the retina of STZ-induced animal models [<xref rid="B60" ref-type="bibr">60</xref>], indicating that similar mechanisms might exist in the setting of T1DM. Treatment with vildagliptin in Otsuka Long-Evans Tokushima Fatty rats (OLETF rats), an animal model of obese T2DM, resulted in reduced gene expression levels of inflammatory and thrombogenic markers, such as VEGF, intercellular adhesion molecule 1, PAI-1, and pigment epithelium-derived factor, in the retina [<xref rid="B61" ref-type="bibr">61</xref>], showing beneficial effects of vildagliptin on retinal injury in T2DM animal models.</p><p>Recently, opposing study results were reported by Lee et al. [<xref rid="B15" ref-type="bibr">15</xref>]. Using various <italic>in vivo</italic> and <italic>in vitro</italic> DR models, they demonstrated that DPP-4 inhibitors increased vascular permeability through the SDF-1&#x003b1;/C-X-C chemokine receptor type 4 (CXCR4) axis, followed by Src activation and phosphorylation of VE-cadherin. Because these were the first data showing an association between DPP-4 inhibitors and increased vascular permeability in the retina, albeit preclinical, concerns of the safety of incretin-based drugs with DR in T2DM patients were raised.</p><p>To date, limited clinical studies exist with regard to the effect of DPP-4 inhibitors on EPCs and DR. Fadini et al. [<xref rid="B62" ref-type="bibr">62</xref>] showed that a 4-week administration of sitagliptin elevated circulating EPCs in T2DM human subjects already treated with metformin and/or insulin secretagogues. Moreover, this increased level of EPCs was associated with upregulation of SDF-1&#x003b1; [<xref rid="B62" ref-type="bibr">62</xref>], which is a chemokine that promotes the mobilization of EPCs from bone marrow into the circulation by binding to its receptor, CXCR4 [<xref rid="B63" ref-type="bibr">63</xref>]. This finding is consistent with that of the aforementioned preclinical study that observed the amelioration of decreased EPC mobilization upon sitagliptin administration in a T2DM animal model [<xref rid="B57" ref-type="bibr">57</xref>].</p><p>Retinal hyperperfusion is an early hemodynamic change in DR, and a clinical study to investigate the effect of saxagliptin on these early retinal microvascular changes in patients with T2DM was conducted [<xref rid="B63" ref-type="bibr">63</xref>]. In this double-blind, placebo-controlled, cross-over trial of 50 patients with T2DM, 6 weeks of saxagliptin treatment resulted in normalization of the retinal capillary flow and improved central hemodynamics [<xref rid="B64" ref-type="bibr">64</xref>].</p><p>Therefore, taken together, it is plausible that the pharmacologic inhibition of DPP-4 can exert an incretin-independent, retinoprotective effect via the upregulation of the SDF-1&#x003b1;/CXCR4 pathway, which in turn restores the number of EPCs, enhances vascular homeostasis, and possibly normalizes early DR-related hemodynamic changes in the retinas of human subjects with T2DM. A single, opposing preclinical study result would not outweigh the multiple clinical benefits that we have observed from the aforementioned studies to date, but the multiple limitations of these studies do warrant a careful interpretation. Nevertheless, the possibility of DR aggravation by DPP-4 inhibitors should not be overlooked; thereby, emphasizing the need for more clinical data to clarify this disparity and better understand safety outcomes that are associated with the use of DPP-4 inhibitors.</p></sec></sec><sec sec-type="conclusions"><title>CONCLUSIONS</title><p>Incretin-based therapies possess potent, pleiotropic effects that are beneficial in glycemic control and in vascular protection. To date, most GLP-1 RAs and DPP-4 inhibitors have shown good efficacy and safety profiles in both preclinical and clinical studies. The beneficial effects of these incretin-based therapies, through various mechanisms that are dependent and independent of glycemic improvement, indicate additional advantages against microvascular complications beyond glycemic control. Some preclinical and clinical study results have questioned the association between incretin-based therapies and the progression of DR. Due to the limitations of these studies, such as short-term follow-up periods and an imprecise method of evaluating retinopathy, any premature conclusion should be avoided. Nevertheless, in a clinical setting, evaluation of retinopathy before and during the administration of GLP-1 RAs or DPP-4 inhibitors, as well as a slower rate of glycemic control in patients with uncontrolled hyperglycemia prior to administration of these agents might be helpful strategies, given that progression of DR was associated with the existence of retinopathy at baseline and faster HbA1c reduction. Results from upcoming trials, such as the EXSCEL trial of exenatide and the REWIND trial of dulaglutide, are critical to strengthen the potential benefits and to clarify the recently raised concerns regarding the possible association between incretin-based therapies and the progression of DR.</p></sec></body><back><ack><title>ACKNOWLEDGMENTS</title><p>This research was supported by Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education (2015R1D1A1A01057720).</p></ack><fn-group><fn fn-type="COI-statement"><p><bold>CONFLICTS OF INTEREST:</bold> No potential conflict of interest relevant to this article was reported.</p></fn></fn-group><ref-list><ref id="B1"><label>1</label><element-citation publication-type="journal"><collab>UK Prospective Diabetes Study (UKPDS) Group</collab><article-title>Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)</article-title><source>Lancet</source><year>1998</year><volume>352</volume><fpage>837</fpage><lpage>853</lpage><pub-id pub-id-type="pmid">9742976</pub-id></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Holman</surname><given-names>RR</given-names></name><name><surname>Paul</surname><given-names>SK</given-names></name><name><surname>Bethel</surname><given-names>MA</given-names></name><name><surname>Matthews</surname><given-names>DR</given-names></name><name><surname>Neil</surname><given-names>HA</given-names></name></person-group><article-title>10-Year follow-up of intensive glucose control in type 2 diabetes</article-title><source>N Engl J Med</source><year>2008</year><volume>359</volume><fpage>1577</fpage><lpage>1589</lpage><pub-id pub-id-type="pmid">18784090</pub-id></element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="book"><collab>Korean Diabetes Association</collab><source>Diabetes fact sheet in Korea 2016 [Internet]</source><publisher-loc>Seoul</publisher-loc><publisher-name>Korean Diabetes Association</publisher-name><year>c2011</year><date-in-citation content-type="access-date">cited 2017 Aug 7</date-in-citation><comment>Available from: <ext-link ext-link-type="uri" xlink:href="http://www.diabetes.or.kr/temp/KDA_fact_sheet%202016.pdf">http://www.diabetes.or.kr/temp/KDA_fact_sheet%202016.pdf</ext-link></comment></element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aroor</surname><given-names>AR</given-names></name><name><surname>Sowers</surname><given-names>JR</given-names></name><name><surname>Jia</surname><given-names>G</given-names></name><name><surname>DeMarco</surname><given-names>VG</given-names></name></person-group><article-title>Pleiotropic effects of the dipeptidylpeptidase-4 inhibitors on the cardiovascular system</article-title><source>Am J Physiol Heart Circ Physiol</source><year>2014</year><volume>307</volume><fpage>H477</fpage><lpage>H492</lpage><pub-id pub-id-type="pmid">24929856</pub-id></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fava</surname><given-names>S</given-names></name></person-group><article-title>Glucagon-like peptide 1 and the cardiovascular system</article-title><source>Curr Diabetes Rev</source><year>2014</year><volume>10</volume><fpage>302</fpage><lpage>310</lpage><pub-id pub-id-type="pmid">25360712</pub-id></element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kang</surname><given-names>YM</given-names></name><name><surname>Jung</surname><given-names>CH</given-names></name></person-group><article-title>Cardiovascular effects of glucagon-like peptide-1 receptor agonists</article-title><source>Endocrinol Metab (Seoul)</source><year>2016</year><volume>31</volume><fpage>258</fpage><lpage>274</lpage><pub-id pub-id-type="pmid">27118277</pub-id></element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Simo</surname><given-names>R</given-names></name><name><surname>Hernandez</surname><given-names>C</given-names></name></person-group><article-title>GLP-1R as a target for the treatment of diabetic retinopathy: friend or foe?</article-title><source>Diabetes</source><year>2017</year><volume>66</volume><fpage>1453</fpage><lpage>1460</lpage><pub-id pub-id-type="pmid">28533296</pub-id></element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zoungas</surname><given-names>S</given-names></name><name><surname>Patel</surname><given-names>A</given-names></name><name><surname>Chalmers</surname><given-names>J</given-names></name><name><surname>de Galan</surname><given-names>BE</given-names></name><name><surname>Li</surname><given-names>Q</given-names></name><name><surname>Billot</surname><given-names>L</given-names></name><etal/></person-group><article-title>Severe hypoglycemia and risks of vascular events and death</article-title><source>N Engl J Med</source><year>2010</year><volume>363</volume><fpage>1410</fpage><lpage>1418</lpage><pub-id pub-id-type="pmid">20925543</pub-id></element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Green</surname><given-names>JB</given-names></name><name><surname>Bethel</surname><given-names>MA</given-names></name><name><surname>Armstrong</surname><given-names>PW</given-names></name><name><surname>Buse</surname><given-names>JB</given-names></name><name><surname>Engel</surname><given-names>SS</given-names></name><name><surname>Garg</surname><given-names>J</given-names></name><etal/></person-group><article-title>Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes</article-title><source>N Engl J Med</source><year>2015</year><volume>373</volume><fpage>232</fpage><lpage>242</lpage><pub-id pub-id-type="pmid">26052984</pub-id></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marso</surname><given-names>SP</given-names></name><name><surname>Bain</surname><given-names>SC</given-names></name><name><surname>Consoli</surname><given-names>A</given-names></name><name><surname>Eliaschewitz</surname><given-names>FG</given-names></name><name><surname>Jodar</surname><given-names>E</given-names></name><name><surname>Leiter</surname><given-names>LA</given-names></name><etal/></person-group><article-title>Semaglutide and cardiovascular outcomes in patients with type 2 diabetes</article-title><source>N Engl J Med</source><year>2016</year><volume>375</volume><fpage>1834</fpage><lpage>1844</lpage><pub-id pub-id-type="pmid">27633186</pub-id></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marso</surname><given-names>SP</given-names></name><name><surname>Daniels</surname><given-names>GH</given-names></name><name><surname>Brown-Frandsen</surname><given-names>K</given-names></name><name><surname>Kristensen</surname><given-names>P</given-names></name><name><surname>Mann</surname><given-names>JF</given-names></name><name><surname>Nauck</surname><given-names>MA</given-names></name><etal/></person-group><article-title>Liraglutide and cardiovascular outcomes in type 2 diabetes</article-title><source>N Engl J Med</source><year>2016</year><volume>375</volume><fpage>311</fpage><lpage>322</lpage><pub-id pub-id-type="pmid">27295427</pub-id></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pfeffer</surname><given-names>MA</given-names></name><name><surname>Claggett</surname><given-names>B</given-names></name><name><surname>Diaz</surname><given-names>R</given-names></name><name><surname>Dickstein</surname><given-names>K</given-names></name><name><surname>Gerstein</surname><given-names>HC</given-names></name><name><surname>Kober</surname><given-names>LV</given-names></name><etal/></person-group><article-title>Lixisenatide in patients with type 2 diabetes and acute coronary syndrome</article-title><source>N Engl J Med</source><year>2015</year><volume>373</volume><fpage>2247</fpage><lpage>2257</lpage><pub-id pub-id-type="pmid">26630143</pub-id></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scirica</surname><given-names>BM</given-names></name><name><surname>Bhatt</surname><given-names>DL</given-names></name><name><surname>Braunwald</surname><given-names>E</given-names></name><name><surname>Steg</surname><given-names>PG</given-names></name><name><surname>Davidson</surname><given-names>J</given-names></name><name><surname>Hirshberg</surname><given-names>B</given-names></name><etal/></person-group><article-title>Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus</article-title><source>N Engl J Med</source><year>2013</year><volume>369</volume><fpage>1317</fpage><lpage>1326</lpage><pub-id pub-id-type="pmid">23992601</pub-id></element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>White</surname><given-names>WB</given-names></name><name><surname>Cannon</surname><given-names>CP</given-names></name><name><surname>Heller</surname><given-names>SR</given-names></name><name><surname>Nissen</surname><given-names>SE</given-names></name><name><surname>Bergenstal</surname><given-names>RM</given-names></name><name><surname>Bakris</surname><given-names>GL</given-names></name><etal/></person-group><article-title>Alogliptin after acute coronary syndrome in patients with type 2 diabetes</article-title><source>N Engl J Med</source><year>2013</year><volume>369</volume><fpage>1327</fpage><lpage>1335</lpage><pub-id pub-id-type="pmid">23992602</pub-id></element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>CS</given-names></name><name><surname>Kim</surname><given-names>YG</given-names></name><name><surname>Cho</surname><given-names>HJ</given-names></name><name><surname>Park</surname><given-names>J</given-names></name><name><surname>Jeong</surname><given-names>H</given-names></name><name><surname>Lee</surname><given-names>SE</given-names></name><etal/></person-group><article-title>Dipeptidyl peptidase-4 inhibitor increases vascular leakage in retina through VE-cadherin phosphorylation</article-title><source>Sci Rep</source><year>2016</year><volume>6</volume><fpage>29393</fpage><pub-id pub-id-type="pmid">27381080</pub-id></element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Defronzo</surname><given-names>RA</given-names></name></person-group><article-title>Banting lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus</article-title><source>Diabetes</source><year>2009</year><volume>58</volume><fpage>773</fpage><lpage>795</lpage><pub-id pub-id-type="pmid">19336687</pub-id></element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Silva Junior</surname><given-names>WS</given-names></name><name><surname>Godoy-Matos</surname><given-names>AF</given-names></name><name><surname>Kraemer-Aguiar</surname><given-names>LG</given-names></name></person-group><article-title>Dipeptidyl peptidase 4: a new link between diabetes mellitus and atherosclerosis?</article-title><source>Biomed Res Int</source><year>2015</year><volume>2015</volume><fpage>816164</fpage><pub-id pub-id-type="pmid">26146634</pub-id></element-citation></ref><ref id="B18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamagishi</surname><given-names>S</given-names></name><name><surname>Fukami</surname><given-names>K</given-names></name><name><surname>Matsui</surname><given-names>T</given-names></name></person-group><article-title>Crosstalk between advanced glycation end products (AGEs)-receptor RAGE axis and dipeptidyl peptidase-4-incretin system in diabetic vascular complications</article-title><source>Cardiovasc Diabetol</source><year>2015</year><volume>14</volume><fpage>2</fpage><pub-id pub-id-type="pmid">25582643</pub-id></element-citation></ref><ref id="B19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kawanami</surname><given-names>D</given-names></name><name><surname>Matoba</surname><given-names>K</given-names></name><name><surname>Sango</surname><given-names>K</given-names></name><name><surname>Utsunomiya</surname><given-names>K</given-names></name></person-group><article-title>Incretin-based therapies for diabetic complications: basic mechanisms and clinical evidence</article-title><source>Int J Mol Sci</source><year>2016</year><volume>17</volume><elocation-id>E1223</elocation-id><pub-id pub-id-type="pmid">27483245</pub-id></element-citation></ref><ref id="B20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jung</surname><given-names>CH</given-names></name><name><surname>Lee</surname><given-names>MJ</given-names></name><name><surname>Kang</surname><given-names>YM</given-names></name><name><surname>Hwang</surname><given-names>JY</given-names></name><name><surname>Kim</surname><given-names>EH</given-names></name><name><surname>Park</surname><given-names>JY</given-names></name><etal/></person-group><article-title>The risk of chronic kidney disease in a metabolically healthy obese population</article-title><source>Kidney Int</source><year>2015</year><volume>88</volume><fpage>843</fpage><lpage>850</lpage><pub-id pub-id-type="pmid">26108064</pub-id></element-citation></ref><ref id="B21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Whaley-Connell</surname><given-names>A</given-names></name><name><surname>Bomback</surname><given-names>AS</given-names></name><name><surname>McFarlane</surname><given-names>SI</given-names></name><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Roberts</surname><given-names>T</given-names></name><name><surname>Chen</surname><given-names>SC</given-names></name><etal/></person-group><article-title>Diabetic cardiovascular disease predicts chronic kidney disease awareness in the kidney early evaluation program</article-title><source>Cardiorenal Med</source><year>2011</year><volume>1</volume><fpage>45</fpage><lpage>52</lpage><pub-id pub-id-type="pmid">22258465</pub-id></element-citation></ref><ref id="B22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hadjiyanni</surname><given-names>I</given-names></name><name><surname>Siminovitch</surname><given-names>KA</given-names></name><name><surname>Danska</surname><given-names>JS</given-names></name><name><surname>Drucker</surname><given-names>DJ</given-names></name></person-group><article-title>Glucagon-like peptide-1 receptor signalling selectively regulates murine lymphocyte proliferation and maintenance of peripheral regulatory T cells</article-title><source>Diabetologia</source><year>2010</year><volume>53</volume><fpage>730</fpage><lpage>740</lpage><pub-id pub-id-type="pmid">20225396</pub-id></element-citation></ref><ref id="B23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hamilton</surname><given-names>A</given-names></name><name><surname>Holscher</surname><given-names>C</given-names></name></person-group><article-title>Receptors for the incretin glucagon-like peptide-1 are expressed on neurons in the central nervous system</article-title><source>Neuroreport</source><year>2009</year><volume>20</volume><fpage>1161</fpage><lpage>1166</lpage><pub-id pub-id-type="pmid">19617854</pub-id></element-citation></ref><ref id="B24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hansen</surname><given-names>L</given-names></name><name><surname>Deacon</surname><given-names>CF</given-names></name><name><surname>Orskov</surname><given-names>C</given-names></name><name><surname>Holst</surname><given-names>JJ</given-names></name></person-group><article-title>Glucagon-like peptide-1-(7-36)amide is transformed to glucagon-like peptide-1-(9-36)amide by dipeptidyl peptidase IV in the capillaries supplying the L cells of the porcine intestine</article-title><source>Endocrinology</source><year>1999</year><volume>140</volume><fpage>5356</fpage><lpage>5363</lpage><pub-id pub-id-type="pmid">10537167</pub-id></element-citation></ref><ref id="B25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hansen</surname><given-names>LB</given-names></name></person-group><article-title>GLP-2 and mesenteric blood flow</article-title><source>Dan Med J</source><year>2013</year><volume>60</volume><fpage>B4634</fpage><pub-id pub-id-type="pmid">23673268</pub-id></element-citation></ref><ref id="B26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harrison</surname><given-names>DG</given-names></name><name><surname>Marvar</surname><given-names>PJ</given-names></name><name><surname>Titze</surname><given-names>JM</given-names></name></person-group><article-title>Vascular inflammatory cells in hypertension</article-title><source>Front Physiol</source><year>2012</year><volume>3</volume><fpage>128</fpage><pub-id pub-id-type="pmid">22586409</pub-id></element-citation></ref><ref id="B27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mima</surname><given-names>A</given-names></name><name><surname>Hiraoka-Yamomoto</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>Q</given-names></name><name><surname>Kitada</surname><given-names>M</given-names></name><name><surname>Li</surname><given-names>C</given-names></name><name><surname>Geraldes</surname><given-names>P</given-names></name><etal/></person-group><article-title>Protective effects of GLP-1 on glomerular endothelium and its inhibition by PKC&#x003b2; activation in diabetes</article-title><source>Diabetes</source><year>2012</year><volume>61</volume><fpage>2967</fpage><lpage>2979</lpage><pub-id pub-id-type="pmid">22826029</pub-id></element-citation></ref><ref id="B28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ishibashi</surname><given-names>Y</given-names></name><name><surname>Nishino</surname><given-names>Y</given-names></name><name><surname>Matsui</surname><given-names>T</given-names></name><name><surname>Takeuchi</surname><given-names>M</given-names></name><name><surname>Yamagishi</surname><given-names>S</given-names></name></person-group><article-title>Glucagon-like peptide-1 suppresses advanced glycation end product-induced monocyte chemoattractant protein-1 expression in mesangial cells by reducing advanced glycation end product receptor level</article-title><source>Metabolism</source><year>2011</year><volume>60</volume><fpage>1271</fpage><lpage>1277</lpage><pub-id pub-id-type="pmid">21388644</pub-id></element-citation></ref><ref id="B29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hendarto</surname><given-names>H</given-names></name><name><surname>Inoguchi</surname><given-names>T</given-names></name><name><surname>Maeda</surname><given-names>Y</given-names></name><name><surname>Ikeda</surname><given-names>N</given-names></name><name><surname>Zheng</surname><given-names>J</given-names></name><name><surname>Takei</surname><given-names>R</given-names></name><etal/></person-group><article-title>GLP-1 analog liraglutide protects against oxidative stress and albuminuria in streptozotocin-induced diabetic rats via protein kinase A-mediated inhibition of renal NAD(P)H oxidases</article-title><source>Metabolism</source><year>2012</year><volume>61</volume><fpage>1422</fpage><lpage>1434</lpage><pub-id pub-id-type="pmid">22554832</pub-id></element-citation></ref><ref id="B30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Hu</surname><given-names>C</given-names></name><name><surname>Lu</surname><given-names>W</given-names></name></person-group><article-title>Exenatide reduces urinary transforming growth factor-&#x003b2;1 and type IV collagen excretion in patients with type 2 diabetes and microalbuminuria</article-title><source>Kidney Blood Press Res</source><year>2012</year><volume>35</volume><fpage>483</fpage><lpage>488</lpage><pub-id pub-id-type="pmid">22687869</pub-id></element-citation></ref><ref id="B31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gutzwiller</surname><given-names>JP</given-names></name><name><surname>Tschopp</surname><given-names>S</given-names></name><name><surname>Bock</surname><given-names>A</given-names></name><name><surname>Zehnder</surname><given-names>CE</given-names></name><name><surname>Huber</surname><given-names>AR</given-names></name><name><surname>Kreyenbuehl</surname><given-names>M</given-names></name><etal/></person-group><article-title>Glucagon-like peptide 1 induces natriuresis in healthy subjects and in insulin-resistant obese men</article-title><source>J Clin Endocrinol Metab</source><year>2004</year><volume>89</volume><fpage>3055</fpage><lpage>3061</lpage><pub-id pub-id-type="pmid">15181098</pub-id></element-citation></ref><ref id="B32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>von Scholten</surname><given-names>BJ</given-names></name><name><surname>Lajer</surname><given-names>M</given-names></name><name><surname>Goetze</surname><given-names>JP</given-names></name><name><surname>Persson</surname><given-names>F</given-names></name><name><surname>Rossing</surname><given-names>P</given-names></name></person-group><article-title>Time course and mechanisms of the anti-hypertensive and renal effects of liraglutide treatment</article-title><source>Diabet Med</source><year>2015</year><volume>32</volume><fpage>343</fpage><lpage>352</lpage><pub-id pub-id-type="pmid">25251901</pub-id></element-citation></ref><ref id="B33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>von Scholten</surname><given-names>BJ</given-names></name><name><surname>Hansen</surname><given-names>TW</given-names></name><name><surname>Goetze</surname><given-names>JP</given-names></name><name><surname>Persson</surname><given-names>F</given-names></name><name><surname>Rossing</surname><given-names>P</given-names></name></person-group><article-title>Glucagon-like peptide 1 receptor agonist (GLP-1 RA): long-term effect on kidney function in patients with type 2 diabetes</article-title><source>J Diabetes Complications</source><year>2015</year><volume>29</volume><fpage>670</fpage><lpage>674</lpage><pub-id pub-id-type="pmid">25935863</pub-id></element-citation></ref><ref id="B34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kodera</surname><given-names>R</given-names></name><name><surname>Shikata</surname><given-names>K</given-names></name><name><surname>Takatsuka</surname><given-names>T</given-names></name><name><surname>Oda</surname><given-names>K</given-names></name><name><surname>Miyamoto</surname><given-names>S</given-names></name><name><surname>Kajitani</surname><given-names>N</given-names></name><etal/></person-group><article-title>Dipeptidyl peptidase-4 inhibitor ameliorates early renal injury through its anti-inflammatory action in a rat model of type 1 diabetes</article-title><source>Biochem Biophys Res Commun</source><year>2014</year><volume>443</volume><fpage>828</fpage><lpage>833</lpage><pub-id pub-id-type="pmid">24342619</pub-id></element-citation></ref><ref id="B35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>WJ</given-names></name><name><surname>Xie</surname><given-names>SH</given-names></name><name><surname>Liu</surname><given-names>YN</given-names></name><name><surname>Kim</surname><given-names>W</given-names></name><name><surname>Jin</surname><given-names>HY</given-names></name><name><surname>Park</surname><given-names>SK</given-names></name><etal/></person-group><article-title>Dipeptidyl peptidase IV inhibitor attenuates kidney injury in streptozotocin-induced diabetic rats</article-title><source>J Pharmacol Exp Ther</source><year>2012</year><volume>340</volume><fpage>248</fpage><lpage>255</lpage><pub-id pub-id-type="pmid">22025647</pub-id></element-citation></ref><ref id="B36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marques</surname><given-names>C</given-names></name><name><surname>Mega</surname><given-names>C</given-names></name><name><surname>Goncalves</surname><given-names>A</given-names></name><name><surname>Rodrigues-Santos</surname><given-names>P</given-names></name><name><surname>Teixeira-Lemos</surname><given-names>E</given-names></name><name><surname>Teixeira</surname><given-names>F</given-names></name><etal/></person-group><article-title>Sitagliptin prevents inflammation and apoptotic cell death in the kidney of type 2 diabetic animals</article-title><source>Mediators Inflamm</source><year>2014</year><volume>2014</volume><fpage>538737</fpage><pub-id pub-id-type="pmid">24817793</pub-id></element-citation></ref><ref id="B37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nakashima</surname><given-names>S</given-names></name><name><surname>Matsui</surname><given-names>T</given-names></name><name><surname>Takeuchi</surname><given-names>M</given-names></name><name><surname>Yamagishi</surname><given-names>SI</given-names></name></person-group><article-title>Linagliptin blocks renal damage in type 1 diabetic rats by suppressing advanced glycation end products-receptor axis</article-title><source>Horm Metab Res</source><year>2014</year><volume>46</volume><fpage>717</fpage><lpage>721</lpage><pub-id pub-id-type="pmid">24710699</pub-id></element-citation></ref><ref id="B38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vavrinec</surname><given-names>P</given-names></name><name><surname>Henning</surname><given-names>RH</given-names></name><name><surname>Landheer</surname><given-names>SW</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Deelman</surname><given-names>LE</given-names></name><name><surname>Dokkum</surname><given-names>RP</given-names></name><etal/></person-group><article-title>Vildagliptin restores renal myogenic function and attenuates renal sclerosis independently of effects on blood glucose or proteinuria in Zucker diabetic fatty rat</article-title><source>Curr Vasc Pharmacol</source><year>2014</year><volume>12</volume><fpage>836</fpage><lpage>844</lpage><pub-id pub-id-type="pmid">24066937</pub-id></element-citation></ref><ref id="B39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jackson</surname><given-names>EK</given-names></name><name><surname>Dubinion</surname><given-names>JH</given-names></name><name><surname>Mi</surname><given-names>Z</given-names></name></person-group><article-title>Effects of dipeptidyl peptidase IV inhibition on arterial blood pressure</article-title><source>Clin Exp Pharmacol Physiol</source><year>2008</year><volume>35</volume><fpage>29</fpage><lpage>34</lpage><pub-id pub-id-type="pmid">18047624</pub-id></element-citation></ref><ref id="B40"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tofovic</surname><given-names>DS</given-names></name><name><surname>Bilan</surname><given-names>VP</given-names></name><name><surname>Jackson</surname><given-names>EK</given-names></name></person-group><article-title>Sitagliptin augments angiotensin II-induced renal vasoconstriction in kidneys from rats with metabolic syndrome</article-title><source>Clin Exp Pharmacol Physiol</source><year>2010</year><volume>37</volume><fpage>689</fpage><lpage>691</lpage><pub-id pub-id-type="pmid">20374254</pub-id></element-citation></ref><ref id="B41"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hattori</surname><given-names>S</given-names></name></person-group><article-title>Sitagliptin reduces albuminuria in patients with type 2 diabetes</article-title><source>Endocr J</source><year>2011</year><volume>58</volume><fpage>69</fpage><lpage>73</lpage><pub-id pub-id-type="pmid">21206136</pub-id></element-citation></ref><ref id="B42"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fujita</surname><given-names>H</given-names></name><name><surname>Taniai</surname><given-names>H</given-names></name><name><surname>Murayama</surname><given-names>H</given-names></name><name><surname>Ohshiro</surname><given-names>H</given-names></name><name><surname>Hayashi</surname><given-names>H</given-names></name><name><surname>Sato</surname><given-names>S</given-names></name><etal/></person-group><article-title>DPP-4 inhibition with alogliptin on top of angiotensin II type 1 receptor blockade ameliorates albuminuria via up-regulation of SDF-1&#x003b1; in type 2 diabetic patients with incipient nephropathy</article-title><source>Endocr J</source><year>2014</year><volume>61</volume><fpage>159</fpage><lpage>166</lpage><pub-id pub-id-type="pmid">24225429</pub-id></element-citation></ref><ref id="B43"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tani</surname><given-names>S</given-names></name><name><surname>Nagao</surname><given-names>K</given-names></name><name><surname>Hirayama</surname><given-names>A</given-names></name></person-group><article-title>Association between urinary albumin excretion and low-density lipoprotein heterogeneity following treatment of type 2 diabetes patients with the dipeptidyl peptidase-4 inhibitor, vildagliptin: a pilot study</article-title><source>Am J Cardiovasc Drugs</source><year>2013</year><volume>13</volume><fpage>443</fpage><lpage>450</lpage><pub-id pub-id-type="pmid">23990203</pub-id></element-citation></ref><ref id="B44"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Groop</surname><given-names>PH</given-names></name><name><surname>Cooper</surname><given-names>ME</given-names></name><name><surname>Perkovic</surname><given-names>V</given-names></name><name><surname>Emser</surname><given-names>A</given-names></name><name><surname>Woerle</surname><given-names>HJ</given-names></name><name><surname>von Eynatten</surname><given-names>M</given-names></name></person-group><article-title>Linagliptin lowers albuminuria on top of recommended standard treatment in patients with type 2 diabetes and renal dysfunction</article-title><source>Diabetes Care</source><year>2013</year><volume>36</volume><fpage>3460</fpage><lpage>3468</lpage><pub-id pub-id-type="pmid">24026560</pub-id></element-citation></ref><ref id="B45"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Avogaro</surname><given-names>A</given-names></name><name><surname>Fadini</surname><given-names>GP</given-names></name></person-group><article-title>The effects of dipeptidyl peptidase-4 inhibition on microvascular diabetes complications</article-title><source>Diabetes Care</source><year>2014</year><volume>37</volume><fpage>2884</fpage><lpage>2894</lpage><pub-id pub-id-type="pmid">25249673</pub-id></element-citation></ref><ref id="B46"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Groop</surname><given-names>PH</given-names></name><name><surname>Cooper</surname><given-names>ME</given-names></name><name><surname>Perkovic</surname><given-names>V</given-names></name><name><surname>Hocher</surname><given-names>B</given-names></name><name><surname>Kanasaki</surname><given-names>K</given-names></name><name><surname>Haneda</surname><given-names>M</given-names></name><etal/></person-group><article-title>Linagliptin and its effects on hyperglycaemia and albuminuria in patients with type 2 diabetes and renal dysfunction: the randomized MARLINA-T2 trial</article-title><source>Diabetes Obes Metab</source><year>2017</year><month>6</month><day>21</day><pub-id pub-id-type="doi">10.1111/dom.13041</pub-id><comment>[Epub]</comment></element-citation></ref><ref id="B47"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klein</surname><given-names>R</given-names></name><name><surname>Klein</surname><given-names>BE</given-names></name><name><surname>Moss</surname><given-names>SE</given-names></name></person-group><article-title>Epidemiology of proliferative diabetic retinopathy</article-title><source>Diabetes Care</source><year>1992</year><volume>15</volume><fpage>1875</fpage><lpage>1891</lpage><pub-id pub-id-type="pmid">1464243</pub-id></element-citation></ref><ref id="B48"><label>48</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Antonetti</surname><given-names>DA</given-names></name><name><surname>Barber</surname><given-names>AJ</given-names></name><name><surname>Bronson</surname><given-names>SK</given-names></name><name><surname>Freeman</surname><given-names>WM</given-names></name><name><surname>Gardner</surname><given-names>TW</given-names></name><name><surname>Jefferson</surname><given-names>LS</given-names></name><etal/></person-group><article-title>Diabetic retinopathy: seeing beyond glucose-induced microvascular disease</article-title><source>Diabetes</source><year>2006</year><volume>55</volume><fpage>2401</fpage><lpage>2411</lpage><pub-id pub-id-type="pmid">16936187</pub-id></element-citation></ref><ref id="B49"><label>49</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hernandez</surname><given-names>C</given-names></name><name><surname>Bogdanov</surname><given-names>P</given-names></name><name><surname>Corraliza</surname><given-names>L</given-names></name><name><surname>Garcia-Ramirez</surname><given-names>M</given-names></name><name><surname>Sola-Adell</surname><given-names>C</given-names></name><name><surname>Arranz</surname><given-names>JA</given-names></name><etal/></person-group><article-title>Topical administration of GLP-1 receptor agonists prevents retinal neurodegeneration in experimental diabetes</article-title><source>Diabetes</source><year>2016</year><volume>65</volume><fpage>172</fpage><lpage>187</lpage><pub-id pub-id-type="pmid">26384381</pub-id></element-citation></ref><ref id="B50"><label>50</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cunha-Vaz</surname><given-names>J</given-names></name><name><surname>Faria de Abreu</surname><given-names>JR</given-names></name><name><surname>Campos</surname><given-names>AJ</given-names></name></person-group><article-title>Early breakdown of the blood-retinal barrier in diabetes</article-title><source>Br J Ophthalmol</source><year>1975</year><volume>59</volume><fpage>649</fpage><lpage>656</lpage><pub-id pub-id-type="pmid">1203221</pub-id></element-citation></ref><ref id="B51"><label>51</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goncalves</surname><given-names>A</given-names></name><name><surname>Lin</surname><given-names>CM</given-names></name><name><surname>Muthusamy</surname><given-names>A</given-names></name><name><surname>Fontes-Ribeiro</surname><given-names>C</given-names></name><name><surname>Ambrosio</surname><given-names>AF</given-names></name><name><surname>Abcouwer</surname><given-names>SF</given-names></name><etal/></person-group><article-title>Protective effect of a GLP-1 analog on ischemia-reperfusion induced blood-retinal barrier breakdown and inflammation</article-title><source>Invest Ophthalmol Vis Sci</source><year>2016</year><volume>57</volume><fpage>2584</fpage><lpage>2592</lpage><pub-id pub-id-type="pmid">27163772</pub-id></element-citation></ref><ref id="B52"><label>52</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abcouwer</surname><given-names>SF</given-names></name><name><surname>Lin</surname><given-names>CM</given-names></name><name><surname>Wolpert</surname><given-names>EB</given-names></name><name><surname>Shanmugam</surname><given-names>S</given-names></name><name><surname>Schaefer</surname><given-names>EW</given-names></name><name><surname>Freeman</surname><given-names>WM</given-names></name><etal/></person-group><article-title>Effects of ischemic preconditioning and bevacizumab on apoptosis and vascular permeability following retinal ischemia-reperfusion injury</article-title><source>Invest Ophthalmol Vis Sci</source><year>2010</year><volume>51</volume><fpage>5920</fpage><lpage>5933</lpage><pub-id pub-id-type="pmid">20554620</pub-id></element-citation></ref><ref id="B53"><label>53</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fan</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>K</given-names></name><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Ruan</surname><given-names>Y</given-names></name><name><surname>Ye</surname><given-names>W</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name></person-group><article-title>Exendin-4 alleviates retinal vascular leakage by protecting the blood-retinal barrier and reducing retinal vascular permeability in diabetic Goto-Kakizaki rats</article-title><source>Exp Eye Res</source><year>2014</year><volume>127</volume><fpage>104</fpage><lpage>116</lpage><pub-id pub-id-type="pmid">24910901</pub-id></element-citation></ref><ref id="B54"><label>54</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Varadhan</surname><given-names>L</given-names></name><name><surname>Humphreys</surname><given-names>T</given-names></name><name><surname>Hariman</surname><given-names>C</given-names></name><name><surname>Walker</surname><given-names>AB</given-names></name><name><surname>Varughese</surname><given-names>GI</given-names></name></person-group><article-title>GLP-1 agonist treatment: implications for diabetic retinopathy screening</article-title><source>Diabetes Res Clin Pract</source><year>2011</year><volume>94</volume><fpage>e68</fpage><lpage>e71</lpage><pub-id pub-id-type="pmid">21906831</pub-id></element-citation></ref><ref id="B55"><label>55</label><element-citation publication-type="journal"><collab>The Diabetes Control and Complications Trial Research Group</collab><article-title>Early worsening of diabetic retinopathy in the Diabetes Control and Complications Trial</article-title><source>Arch Ophthalmol</source><year>1998</year><volume>116</volume><fpage>874</fpage><lpage>886</lpage><pub-id pub-id-type="pmid">9682700</pub-id></element-citation></ref><ref id="B56"><label>56</label><element-citation publication-type="confproc"><person-group person-group-type="author"><name><surname>Vilsboll</surname><given-names>T</given-names></name></person-group><source>Cardiovascular outcomes with semaglutide in subjects with type 2 diabetes mellitus (SUSTAIN 6) (presentation 1-AC-SY09)</source><conf-name>Paper presented at: 77th Scientific Sessions, American Diabetes Association 2017</conf-name><conf-date>2017 Jun 9-13</conf-date><conf-loc>San Diego, CA</conf-loc></element-citation></ref><ref id="B57"><label>57</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goncalves</surname><given-names>A</given-names></name><name><surname>Leal</surname><given-names>E</given-names></name><name><surname>Paiva</surname><given-names>A</given-names></name><name><surname>Teixeira Lemos</surname><given-names>E</given-names></name><name><surname>Teixeira</surname><given-names>F</given-names></name><name><surname>Ribeiro</surname><given-names>CF</given-names></name><etal/></person-group><article-title>Protective effects of the dipeptidyl peptidase IV inhibitor sitagliptin in the blood-retinal barrier in a type 2 diabetes animal model</article-title><source>Diabetes Obes Metab</source><year>2012</year><volume>14</volume><fpage>454</fpage><lpage>463</lpage><pub-id pub-id-type="pmid">22151893</pub-id></element-citation></ref><ref id="B58"><label>58</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fadini</surname><given-names>GP</given-names></name><name><surname>Agostini</surname><given-names>C</given-names></name><name><surname>Sartore</surname><given-names>S</given-names></name><name><surname>Avogaro</surname><given-names>A</given-names></name></person-group><article-title>Endothelial progenitor cells in the natural history of atherosclerosis</article-title><source>Atherosclerosis</source><year>2007</year><volume>194</volume><fpage>46</fpage><lpage>54</lpage><pub-id pub-id-type="pmid">17493626</pub-id></element-citation></ref><ref id="B59"><label>59</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fadini</surname><given-names>GP</given-names></name><name><surname>Sartore</surname><given-names>S</given-names></name><name><surname>Albiero</surname><given-names>M</given-names></name><name><surname>Baesso</surname><given-names>I</given-names></name><name><surname>Murphy</surname><given-names>E</given-names></name><name><surname>Menegolo</surname><given-names>M</given-names></name><etal/></person-group><article-title>Number and function of endothelial progenitor cells as a marker of severity for diabetic vasculopathy</article-title><source>Arterioscler Thromb Vasc Biol</source><year>2006</year><volume>26</volume><fpage>2140</fpage><lpage>2146</lpage><pub-id pub-id-type="pmid">16857948</pub-id></element-citation></ref><ref id="B60"><label>60</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goncalves</surname><given-names>A</given-names></name><name><surname>Marques</surname><given-names>C</given-names></name><name><surname>Leal</surname><given-names>E</given-names></name><name><surname>Ribeiro</surname><given-names>CF</given-names></name><name><surname>Reis</surname><given-names>F</given-names></name><name><surname>Ambrosio</surname><given-names>AF</given-names></name><etal/></person-group><article-title>Dipeptidyl peptidase-IV inhibition prevents blood-retinal barrier breakdown, inflammation and neuronal cell death in the retina of type 1 diabetic rats</article-title><source>Biochim Biophys Acta</source><year>2014</year><volume>1842</volume><fpage>1454</fpage><lpage>1463</lpage><pub-id pub-id-type="pmid">24769045</pub-id></element-citation></ref><ref id="B61"><label>61</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maeda</surname><given-names>S</given-names></name><name><surname>Yamagishi</surname><given-names>S</given-names></name><name><surname>Matsui</surname><given-names>T</given-names></name><name><surname>Nakashima</surname><given-names>S</given-names></name><name><surname>Ojima</surname><given-names>A</given-names></name><name><surname>Maeda</surname><given-names>S</given-names></name><etal/></person-group><article-title>Beneficial effects of vildagliptin on retinal injury in obese type 2 diabetic rats</article-title><source>Ophthalmic Res</source><year>2013</year><volume>50</volume><fpage>221</fpage><lpage>226</lpage><pub-id pub-id-type="pmid">24081217</pub-id></element-citation></ref><ref id="B62"><label>62</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fadini</surname><given-names>GP</given-names></name><name><surname>Boscaro</surname><given-names>E</given-names></name><name><surname>Albiero</surname><given-names>M</given-names></name><name><surname>Menegazzo</surname><given-names>L</given-names></name><name><surname>Frison</surname><given-names>V</given-names></name><name><surname>de Kreutzenberg</surname><given-names>S</given-names></name><etal/></person-group><article-title>The oral dipeptidyl peptidase-4 inhibitor sitagliptin increases circulating endothelial progenitor cells in patients with type 2 diabetes: possible role of stromal-derived factor-1alpha</article-title><source>Diabetes Care</source><year>2010</year><volume>33</volume><fpage>1607</fpage><lpage>1609</lpage><pub-id pub-id-type="pmid">20357375</pub-id></element-citation></ref><ref id="B63"><label>63</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Petit</surname><given-names>I</given-names></name><name><surname>Jin</surname><given-names>D</given-names></name><name><surname>Rafii</surname><given-names>S</given-names></name></person-group><article-title>The SDF-1-CXCR4 signaling pathway: a molecular hub modulating neo-angiogenesis</article-title><source>Trends Immunol</source><year>2007</year><volume>28</volume><fpage>299</fpage><lpage>307</lpage><pub-id pub-id-type="pmid">17560169</pub-id></element-citation></ref><ref id="B64"><label>64</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ott</surname><given-names>C</given-names></name><name><surname>Raff</surname><given-names>U</given-names></name><name><surname>Schmidt</surname><given-names>S</given-names></name><name><surname>Kistner</surname><given-names>I</given-names></name><name><surname>Friedrich</surname><given-names>S</given-names></name><name><surname>Bramlage</surname><given-names>P</given-names></name><etal/></person-group><article-title>Effects of saxagliptin on early microvascular changes in patients with type 2 diabetes</article-title><source>Cardiovasc Diabetol</source><year>2014</year><volume>13</volume><fpage>19</fpage><pub-id pub-id-type="pmid">24423149</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="F1" orientation="portrait" position="float"><label>Fig. 1</label><caption><title>Schematic representation of the pleiotropic effect of incretin-based drugs with respect to chronic diabetic vascular complications. Modified from Aroor et al. [4], with permission from American Physiological Society. GLP-1 RA, glucagon-like peptide-1 receptor agonist; GLP-1R, glucagon-like peptide-1 receptor; GIP, gastric inhibitory peptide; AGE, advanced glycation end product; DPP-4, dipeptidyl peptidase-4; SDF-1&#x003b1;, stromal cell-derived factor 1&#x003b1;; EPC, endothelial progenitor cell; BNP, brain natriuretic peptide; NPY-1, neuropeptide Y-1; IL, interleukin.</title></caption><graphic xlink:href="enm-32-316-g001"/></fig></floats-group></article>